ZOMP is a UK-based medical device company specializing in the development of advanced 3D imaging flow cytometers for the life sciences sector. Founded in 2022, the company aims to revolutionize cellular analysis and sorting by providing high-throughput, sub-cellular resolution imaging solutions.
Key Strategic Focus
ZOMP's strategic focus centers on delivering innovative 3D imaging cytometry and cell sorting technologies. Their proprietary platform offers accurate measurement and sorting of single cells at high throughput, based on observable characteristics. This technology is designed to enhance disease deciphering capabilities, targeting the health tech industry and research institutions.
Financials and Funding
In April 2023, ZOMP secured a Series 1 funding round amounting to $2.5 million. Notable investors include BGF, Cambridge Enterprise, Foresight Group, Foresight WAE Technology, and Parkwalk Advisors. The capital is intended to advance product development, expand operational capabilities, and accelerate market entry strategies.
Technological Platform and Innovation
ZOMP's technological platform is distinguished by its 3D imaging flow cytometry capabilities, offering sub-cellular resolution across multiple fluorescence channels at a rate of 1,000 events per second. This innovation enables precise analysis and sorting of single cells, facilitating advanced research in disease mechanisms and therapeutic development.
Leadership Team
- Kevin O'Holleran: Co-Founder & Chief Executive Officer
- Gillies Kleboe: Co-Founder, Chief Business Officer, and Chief Operating Officer
- Steven Lee: Co-Founder & Chief Scientific Officer
These leaders bring extensive experience in medical device development, business operations, and scientific research, driving ZOMP's mission to innovate in cellular analysis technologies.
Leadership Changes
As of July 26, 2024, Steven Lee resigned from his position as a director. His contributions as Co-Founder and Chief Scientific Officer were instrumental in the company's early development.
Competitor Profile
Market Insights and Dynamics: The market for advanced flow cytometry and cell sorting technologies is experiencing significant growth, driven by increasing demand for high-resolution cellular analysis in research and clinical applications.
Competitor Analysis: Key competitors include FluidDA, Orflo Technologies, Illumina, ST Cytonome, and Nabsys. These companies focus on various aspects of cellular analysis and sorting, employing technologies such as imaging cytometry, molecular diagnostics, and genomic analysis.
Strategic Collaborations and Partnerships
ZOMP has established partnerships with leading research institutions and industry stakeholders to enhance its technological offerings and expand its market reach. These collaborations aim to integrate ZOMP's 3D imaging cytometry solutions into broader research and clinical workflows.
Operational Insights
ZOMP's strategic positioning emphasizes its unique 3D imaging capabilities, setting it apart from competitors that may offer traditional flow cytometry solutions. The company's focus on high-throughput, sub-cellular resolution imaging provides a distinct competitive advantage in the market.
Strategic Opportunities and Future Directions
Looking ahead, ZOMP plans to expand its product portfolio, enhance technological capabilities, and enter new markets. The company aims to leverage its strengths in 3D imaging cytometry to address emerging needs in personalized medicine, drug discovery, and disease research.
Contact Information
Note: Specific contact details such as email addresses and physical addresses are not provided in this profile.
